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period in France and in Italy. For assessing the inpatients
costs, we used the National inpatient Diagnosis Group
data base in France and in Italy. We studied the patient
profile, the mean length of stay and the subsequent com-
plications. Data on outpatient care for DVT were based
on literature, questionnaire filled in by practitionners,
ambulatory care data base (in France) and compared to
practice guidelines. Inpatient and outpatient costs were
combined to provide total costs of care for DVT over an
one-year period. In addition, we modelled, from pub-
lished data, the risk of pulmonary embolism (PE) and
DVT recurrences, and we costed these complications.
RESULTS: The average French inpatient cost for DVT is
3,220 Euros (average length of hospital stay: 9.6 days)
while this cost is 2,865 Euros in Italy (average length of
hospital stay: 7 days). In both countries, the total cost of
management of a DVT patient over an one-year period
was calculated to be at least 30% higher than the only
costs of acute care. CONCLUSION: The assessment of
the global economic burden of DVT has to take into ac-
count the costs occurring after hospital discharge. Our
approach was conservative as we did not take into ac-
count the risk of occurrence of Post Phlebitic Syndrome
and its economic consequences.
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BACKGROUND: In recent years, significant advances
have been made in the pharmaceutical treatment of coro-
nary syndromes. The GPIIb/IIIa receptor antagonists
have been shown to increase the success rate of invasive
procedures, such as PTCA. However, acquisition costs
for these agents are high when compared with traditional
therapy (i.e., heparin). Three GPIIb/IIIa receptor antago-
nists have been approved for use by the US Food and
Drug Administration. OBJECTIVE: To assess the relative
cost-effectiveness of abciximab, eptifibatide, and tirofi-
ban when treating US patients with coronary syndromes.
METHODS: A decision analytic model compared the
three drugs on the basis of major bleeding events and myo-
cardial infarction. Costs included those for medications
and adverse events. Transition probabilities were based
on published trials and clinical judgement. The time hori-
zon for the model was 30 days. Cost-effectiveness ratios
were computed for the three agents and rank order stabil-
ity analysis used to test the robustness of results. A hospi-
tal perspective was adopted for the analysis. RESULTS:
Average per-patient treatment cost was $1,393, $2,480,
and $2,409 for eptifibatide, abciximab, and tirofiban, re-
spectively. The probability of successful treatment (i.e.,
no bleeding or myocardial infarction) was 0.86, 0.89,
and 0.78 for eptifibatide, abciximab, and tirofiban, re-
spectively. The cost per successfully treated patient was
$1,616, $2,799, and $3,080 for eptifibatide, abciximab,
and tirofiban, respectively. The incremental cost of eptifi-
batide was $45,292 less than abciximab and $12,700 less
than tirofiban per successfully treated patient. Estimates
of cost-effectiveness were robust to alterations in model
parameters. In order for eptifibatide and abciximab to be
equally cost-effective, the bleeding rate for eptifibatide
would have to increase by 26.9% or the probability of
myocardial infarction for eptifibatide would have to in-
crease by 12.8%. CONCLUSIONS: Results indicate that
the higher costs of abciximab and tirofiban may not be
justified when treating US patients with coronary syn-
dromes. Our model was limited by the availability of
event probability estimates for eptifibatide and tirofiban.
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OBJECTIVE: To study patterns of medical resource utili-
zation among VA patients following admission to VA
hospitals for acute ischemic stroke. METHODS: All VA
patients were identified with a first-listed live discharge
diagnosis of acute ischemic stroke between 1991 and
1997. The frequency and type of re-admissions, total bed
section days, and of outpatient clinic visits was measured.
RESULTS: A total of 49,101 patients were identified.
Mean age of the predominantly male (98.2%) cohort was
67.8 years and 72.5% were Caucasian. Over 48% of pa-
tients were re-hospitalized, and 13% of these re-admis-
sions were for recurrent stroke. There were an average of
3.3 re-admissions and the mean time to readmission was
0.9 years. Readmitted patients spent most days in reha-
bilitation wards (26.8 days), followed bygeneral/acute
medicine wards (22.5 days), surgery (15.1 days). neurol-
ogy (14.9 days), and cardiology (8.5 days). Thirty-five
percent of outpatient medical clinic visits were to spe-
cialty clinics and 41% of these visits were to neurology
followed by cardiology (22%) and Coumadin clinics
(21%). CONCLUSIONS: Hospitalization for recurrent
stroke is high among VA stroke patients and much of the
inpatient and outpatient resource utilization is associated
with stroke rehabilitation and neurologic care. Efforts
should focus on innovations in acute stroke treatment to
improve the functional status of these patients at the time
of the index admission and reduce the incidence of subse-
quent adverse events.
